HLA-DRB1 and myopathy: These findings provide insights into the role of HLA-DRB1*11 genetic testing in differentiating non-immune muscle toxicity from anti-HMGCR IMNM in patients receiving statins, particularly in settings where autoantibody testing for inflammatory myopathies, skeletal muscle biopsy is unavailable, or conclusive diagnostic studies are obtained.